

Max Jan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5780056/publications.pdf>

Version: 2024-02-01

21
papers

693
citations

933447

10
h-index

1058476

14
g-index

22
all docs

22
docs citations

22
times ranked

772
citing authors

#	ARTICLE	IF	CITATIONS
1	Repurposing the Damage Repair Protein Methyl Guanine Methyl Transferase as a Ligand Inducible Fusion Degron. ACS Chemical Biology, 2022, 17, 24-31.	3.4	4
2	CAR T cell killing requires the IFN γ R pathway in solid but not liquid tumours. Nature, 2022, 604, 563-570.	27.8	150
3	Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia. Cancer Cell, 2022, 40, 494-508.e5.	16.8	54
4	SEAKER cells coordinate cellular immunotherapy with localized chemotherapy. Trends in Pharmacological Sciences, 2022, 43, 804-805.	8.7	1
5	Abstract 3606: Lenalidomide switch control of CAR T-cell phenotype and function via degradable membrane-bound IL-7. Cancer Research, 2022, 82, 3606-3606.	0.9	0
6	Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine. Science Translational Medicine, 2022, 14, .	12.4	10
7	Abstract 569: Mesothelin CAR T cells secreting FAP specific T cell engaging molecule (TEAM) target pancreatic cancer and its tumor microenvironment (TME). Cancer Research, 2022, 82, 569-569.	0.9	0
8	Cancer therapies based on targeted protein degradation " lessons learned with lenalidomide. Nature Reviews Clinical Oncology, 2021, 18, 401-417.	27.6	69
9	Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy. Blood Advances, 2021, 5, 2982-2986.	5.2	45
10	Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide. Science Translational Medicine, 2021, 13, .	12.4	132
11	221 " CRISPR screen identifies loss of IFN γ R signaling and downstream adhesion as a resistance mechanism to CAR T-cell cytotoxicity in solid but not liquid tumors. , 2021, 9, A234-A234.		0
12	772 " MHC-I skewing in mutant calreticulin-positive myeloproliferative neoplasms is countered by heteroclitic peptide cancer vaccination. , 2021, 9, A807-A807.		0
13	Rational Chemical and Genetic Modifications Enhance Avidity and Function of CD70-Directed CAR-T-Cells for Myeloid Leukemia. Blood, 2021, 138, 405-405.	1.4	1
14	Clonal Hematopoiesis is Associated with Reduced Risk of Alzheimer's Disease. Blood, 2021, 138, 5-5.	1.4	15
15	A cryptic imatinib-sensitive G3BP1-PDGFRB rearrangement in a myeloid neoplasm with eosinophilia. Blood Advances, 2020, 4, 445-448.	5.2	11
16	Using an in-Vivo Degron-Based Approach to Interrogate Dependencies of Serially Acquired Mutations - Including DNMT3a-R882 and NPM1c - in Acute Myeloid Leukemia. Blood, 2020, 136, 12-13.	1.4	0
17	444 " MHC-I skewing in mutant calreticulin-positive myeloproliferative neoplasms is countered by heteroclitic peptide cancer vaccination. , 2020, , .		0
18	Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs. Blood, 2019, 134, 160-170.	1.4	41

#	ARTICLE	IF	CITATIONS
19	Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2019, 3, 2199-2204.	5.2	52
20	Clonal hematopoiesis. <i>Seminars in Hematology</i> , 2017, 54, 43-50.	3.4	100
21	Absence of Evidence Implicating Hematopoietic Stem Cells As Common Progenitors for DLBCL Mutations. <i>Blood</i> , 2016, 128, 4107-4107.	1.4	1